Paul van Damme

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

ZipLocal, Inc. is a development stage company. It operates through Canada geographical segments. The company was founded on August 22, 2005 and is headquartered in Toronto, Canada.

Bradmer Pharmaceuticals, Inc. engaged in the development and commercialization of cancer therapies. The company was founded on June 16, 2005 and wass headquartered in Toronto, Canada.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.